Cover Image
市場調查報告書

Octreotide的中國市場分析 (2010∼2019年)

Investigation Report on China Octreotide Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 332767
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Octreotide的中國市場分析 (2010∼2019年) Investigation Report on China Octreotide Market, 2010-2019
出版日期: 2015年06月11日 內容資訊: 英文 30 Pages
簡介

Octreotide在中國由Novartis在2014年推出。目前許多國內廠商製造、銷售學名藥。由於Octreotide可用於治療許多疾病,其需求也急速增加,2005年僅1億人民幣的市場規模,之後便以15.8%的年平均成長率(CAGR)成長,到2014年擴大到4億6600萬人民幣。一般認為今後該趨勢也將持續。

本報告提供中國的Octreotide的市場相關分析,提供您整體市場規模趨勢(過去5年份)和國內價格趨勢,各企業·投藥形態別的市場佔有率,主要製造商簡介,未來性的市場趨勢預測(今後5年份)等調查評估。

第1章 Octreotide的相關概念

  • 症狀
  • 全球市場的銷售情形

第2章 中國的Octreotide市場概況

  • 中國國內的Octreotide專利的申請·認證情形
  • 主要製造商
  • 市場規模

第3章 Octreotide銷售情形分析 (過去5年份)

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售量

第4章 中國的Octreotide市場:主要廠商的市場佔有率分析 (過去5年份)

  • 市場佔有率 (以銷售額為準)
  • 市場佔有率 (以銷售量為準)

第5章 中國的Octreotide市場:各劑型分析 (過去5年份)

  • 各劑型的市場佔有率 (以銷售額為準)
  • 各劑型的市場佔有率 (以銷售量為準)

第6章 Octreotide的醫院用標準價格

  • Sandoz GmbH (AT) (商標名:Sandostatin LAR)
  • Shanghai No.1 Biochemical & Pharmaceutical Co., Ltd
  • Wellso Pharmaceutical Co., Ltd
  • Peking Sunho Pharmaceutical Co., Ltd
  • Sinopharm A-THINK Pharmaceutical Co., Ltd
  • GeneScience Pharmaceuticals Co., Ltd
  • Chengdu Tiantaishan Pharmaceutical Co., Ltd
  • Novartis AG (Sweden ) (商標名:Sandostatin LAR)

第7章 中國國內的Octreotide主要製造商

  • Novartis AG (Switzerland)
  • Chengdu Tiantaishan Pharmaceutical Co., Ltd
  • Sinopharm A-THINK Pharmaceutical Co., Ltd
  • Peking Sunho Pharmaceutical Co., Ltd
  • Shanghai No.1 Biochemical & Pharmaceutical Co., Ltd

第8章 中國的Octreotide市場未來展望 (今後5年份)

  • 市場規模的預測
  • 競爭環境預測

圖表一覽

目錄
Product Code: 1506211

Octreotide, an octapeptide that mimics natural somatostatin, has been widely used in clinic for the treatment of upper gastrointestinal variceal hemorrhage and stomach ulcer bleeding, acute pancreatitis, endocrine tumors.

First approved to be sold in 1996, octreotide was developed by Novartis AG under the trade name of Sandostatin. The approved indications at that time were acromegaly, diarrhea and pancreatic cancer. Due to its sure efficacy and various indications, octreotide has become one of the most highly stressed biosimilar compounds. Octreotide has remained a steady growth ever since its listing and its sales value surpassed USD 1000 million in 2007. Sandostatin's US patent expired in Jun. 2014. Although the generic drug of octreotide made by Sun Pharmaceutical Industries Ltd got FDA's approval in 2008, Novartis's octreotide still brought in sales revenue of USD 1589 million in 2013.

After Octreotide made by Novartis entered China in 2004, many local generic drugs came into the market successively. Octreotide has undergone a fast development in China with annual sales value rising from CNY 100 million in 2005 to CNY 466 million in 2014 and CAGR reaching up to 15.8% during the period of 2005-2014. Octreotide enjoys a vast demand in China. Novartis AG (Sweden), Chengdu Tiantaishan Pharmaceutical Co., Ltd, Sinopharm A-THINK Pharmaceutical Co., Ltd, Peking Sunho Pharmaceutical Co., Ltd and Shanghai No.1 Biochemical & Pharmaceutical Co., Ltd all take up certain shares in the Chinese market, among which Novartis AG (Sweden) has the largest market share of over 70%, sales value in 2014 reaching up to CNY 334 million in 2014.

The market size of octreotide in China is expected to keep growing in the next few years.

Readers can get at least the following information from this report:

  • market size of octreotide in China
  • market share of manufacturers of octreotide in China
  • price of octreotide in Chinese market
  • major manufacturers of octreotide in Chinese market
  • market outlook of octreotide in China

The author suggests the following groups of people purchase this report:

  • manufacturers of drugs for endocrine and metabolic regulation
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Octreotide

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Octreotide in China

  • 2.1. Patent and Approval Status of Octreotide in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Octreotide in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Octreotide in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Octreotide in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Octreotide in Chinese Hospitals in 2014

  • 6.1. Sandoz GmbH (AT) (Trade Name: Sandostatin LAR)
  • 6.2. Shanghai No.1 Biochemical & Pharmaceutical Co., Ltd
  • 6.3. Wellso Pharmaceutical Co., Ltd
  • 6.4. Peking Sunho Pharmaceutical Co., Ltd
  • 6.5. Sinopharm A-THINK Pharmaceutical Co., Ltd
  • 6.6. GeneScience Pharmaceuticals Co., Ltd
  • 6.7. Chengdu Tiantaishan Pharmaceutical Co., Ltd
  • 6.8. Novartis AG (Sweden) (Trade Name: Sandostatin LAR)

7. Major Manufacturers of Octreotide in Chinese Market, 2010-2014

  • 7.1. Novartis AG (Switzerland)
  • 7.2. Chengdu Tiantaishan Pharmaceutical Co., Ltd
  • 7.3. Sinopharm A-THINK Pharmaceutical Co., Ltd
  • 7.4. Peking Sunho Pharmaceutical Co., Ltd
  • 7.5. Shanghai No.1 Biochemical & Pharmaceutical Co., Ltd

8. Market Outlook of Ooctreotide in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Patent and Approval Status of Octreotide in China
  • Chart Sales Status of Octreotide in China, 2010-2014
  • Chart Sales Value of Octreotide in China, 2010-2014
  • Chart Sales Value of Octreotide in Some Regions in China, 2010-2014
  • Chart Sales Volume of Octreotide in China, 2010-2014
  • Chart Market Share of TOP5 Manufacturers of Octreotide for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Octreotide Made by Novartis (Switzerland) in China, 2010-2014
  • Chart Sales Value and Market Share of Octreotide Made by Sinopharm A-THINK in China, 2010-2014
  • Chart Sales Value and Market Share of Octreotide Made by Shanghai No.1 Biochemical & Pharmaceutical in China, 2010-2014
  • Chart Sales Value and Market Share of Octreotide Made by Chengdu Tiantaishan in China, 2010-2014
  • Chart Sales Value and Market Share of Octreotide Injection in China, 2010-2014
  • Chart Price of Octreotide Made by Sandoz GmbH (AT) in Some Chinese Cities in 2014
  • Chart Price of Octreotide Made by Shanghai No.1 Biochemical & Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Octreotide Made by Wellso Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Octreotide Made by Peking Sunho Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Octreotide Made by Sinopharm A-THINK Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Octreotide Made by GeneScience Pharmaceuticals Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Octreotide Made by Chengdu Tiantaishan Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Octreotide Made by Novartis AG (Sweden) in Some Chinese Cities in 2014
Back to Top